Company intelligence / Profile preview

EMBioSys

Massachusetts, United Statesembiosys.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EMBioSys has developed a non-invasive, electrode-free wearable garment that delivers induced electric field (iEF) therapy. Preclinical data show significant anti-metastatic and anti-tumor activity against TNBC in vitro and in vivo. Combination with standard chemotherapies like paclitaxel or capecitabine further enhances efficacy by reducing IC50 values by approximately 50%. The technology is being translated into practical clinical devices with the goal of initiating human trials soon[1][2].

Therapeutic areas: Oncology
Modalities: Non-pharmacological therapyDevice (wearable medical device)Electromagnetic field therapy (induced electric field/iEF therapy)
Industry: Therapeutic Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on EMBioSys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMBioSys.

Explore the full profile